CIPO Patents = 1

EPO Patents = 3

Forward Citations = 7

Loading Chart...

6 inventors (with patents filed for the assignee):

Koji Tamada (8 out of 23 patents)

Tomoya Miyakawa (8 out of 15 patents)

Masaaki Oka (5 out of 15 patents)

4. Shoichi Hazama (5 out of 11 patents)

5. Keiko Udaka (5 out of 13 patents)

6. Shun Doi (3 out of 5 patents)

8 patents: Sort by Forward Citations

1. 11491204 - Composition comprising poly I:C and LAG-3-IGG fusion protein (2022-11-08),

2. 11304997 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell (2022-04-19),

3. 11291718 - Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein (2022-04-05),

4. 10875900 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-12-29),

5. 10842848 - Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein (2020-11-24),

6. 10590179 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-03-17),

7. 10537626 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2020-01-21),

8. 10526388 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells (2020-01-07),

Company Overview

Cytlimic Inc. is a biotechnology company dedicated to developing innovative therapeutics for the treatment of cancer. Our focus is on harnessing the power of the immune system to target and destroy cancer cells. With cutting-edge technology and a team of experienced researchers, we are committed to advancing the field of immuno-oncology and improving outcomes for cancer patients.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

8 Patents

#2,150 in Tokyo

#5,045 in Japan

Tokyo, Japan

Cytlimic Inc.

Forward Citations = 7

6 inventors:

Koji Tamada (8 out of 23 patents)

Tomoya Miyakawa (8 out of 15 patents)

Masaaki Oka (5 out of 15 patents)

4. Shoichi Hazama (5 out of 11 patents)

5. Keiko Udaka (5 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cytlimic Inc.. Retrieved from https://idiyas.com/company/cytlimic

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]